One of the related studies of IL-1β is with acute lymphoblastic leukemia, in which IL-1β is known to induce NF-κB activation; more importantly, in KRAS mutant cancer cells, it leads to drug resistance and increased cancer progression [46]. Here, KRAS is linked to acute lymphoblastic leukemia.